| Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia S Bhatt, MS Pioso, EA Olesinski, B Yilma, JA Ryan, T Mashaka, B Leutz, ... Cancer cell 38 (6), 872-890. e6, 2020 | 89 | 2020 |
| Identification and screening of potent antimicrobial peptides in arthropod genomes D Duwadi, A Shrestha, B Yilma, I Kozlovski, M Sa-Eed, N Dahal, ... Peptides 103, 26-30, 2018 | 33 | 2018 |
| Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re‐induction chemotherapy JS Garcia, S Bhatt, G Fell, AS Sperling, M Burgess, H Keshishian, B Yilma, ... American journal of hematology 95 (3), 245-250, 2020 | 16 | 2020 |
| Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics VW Daniels, JJ Zoeller, N Van Gastel, KE McQueeney, S Parvin, ... Science signaling 14 (686), eabc7405, 2021 | 13 | 2021 |
| Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia E Olesinski, K Bhatia, C Wang, M Pioso, SX Ng, XX Lin, V Sandhu, ... Blood 142, 48, 2023 | 1 | 2023 |
| Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB). KL Yuen, MF Meagher, J Mercer, B Yilma, MC Stoppler, S Fragkogianni, ... Journal of Clinical Oncology 42 (16_suppl), 4520-4520, 2024 | | 2024 |
| A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer O Mosalem, TW Coston, R Imperial, E Mauer, C Thompson, B Yilma, ... The Oncologist, oyae098, 2024 | | 2024 |
| Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts EA Olesinski, KS Bhatia, C Wang, MS Pioso, XX Lin, AM Mamdouh, ... Blood Cancer Discovery 5 (3), 180-201, 2024 | | 2024 |
| Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation Y van der Pol, B Yilma, VK Morris, C Chao, M Harris, J Guinney, S Kopetz Cancer Research 84 (6_Supplement), 5056-5056, 2024 | | 2024 |
| Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations. GT King, R Berg, B Yilma, MC Stoppler, RW Hsieh, RA Safyan, DB Zhen, ... Journal of Clinical Oncology 42 (3_suppl), 557-557, 2024 | | 2024 |
| Trends over Time in Overall Survival of Patients with Multiple Myeloma By Race/Ethnicity and By Comorbidity Status: A Surveillance, Epidemiology, and End Results (SEER … F Anwer, D Goldschmidt, W Tang, DR Steffen, B Yilma, S Slaff Blood 140 (Supplement 1), 10916-10917, 2022 | | 2022 |
| Abstract NG14: Reduction in mitochondrial priming drives resistance to targeted therapy in acute myeloid leukemia S Bhatt, MS Piosos, EA Olesinski, BG Yilma, JA Ryan, T Mashaka, B Leutz, ... Cancer Research 81 (13_Supplement), NG14-NG14, 2021 | | 2021 |
| Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia S Bhatt, M Pioso, EA Olesinski, B Yilma, L Buon, S Adamia, H Zhu, J Ryan, ... Blood 134, 2551, 2019 | | 2019 |
| Individualized functional approach to tailoring acute myeloid leukemia therapy S Bhatt, B Yilma, E Olesinski, H Zhu, M Murakami, VK Murali, S Adamia, ... Cancer Research 79 (13_Supplement), 2990-2990, 2019 | | 2019 |
Anthony LetaiProfessor of Medicine, Dana-Farber Cancer InstituteVerified email at dfci.harvard.edu
